Patents by Inventor Mark Miglarese

Mark Miglarese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic oligonucleotides
    Patent number: 11725023
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: August 15, 2023
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Günter Mayer, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20230250437
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 10, 2023
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Heather O’Neill, Mark Miglarese, David Spetzler
  • THERAPEUTIC OLIGONUCLEOTIDES
    Publication number: 20220356203
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.
    Type: Application
    Filed: February 3, 2021
    Publication date: November 10, 2022
    Inventors: Heather O`Neill, Günter Mayer, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20220290124
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 15, 2022
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20220170021
    Abstract: Methods and compositions are provided for oligonucleotide probes and oligonucleotide probe libraries that recognize targets of interest. The targets include circulating biomarkers such as microvesicles, including those derived from various diseases.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 2, 2022
    Inventors: Valeriy Domenyuk, Adam Stark, Nianqing Xiao, Zhenyu Zhong, Mark Miglarese, David Spetzler
  • Oligonucleotide probes and uses thereof
    Patent number: 11332748
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 17, 2022
    Assignee: Caris Science, Inc.
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Heather O'Neill, Mark Miglarese, David Spetzler
  • Oligonucleotide probes and uses thereof
    Patent number: 11293017
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: April 5, 2022
    Assignee: Caris Science, Inc.
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Mark Miglarese, David Spetzler
  • THERAPEUTIC OLIGONUCLEOTIDES
    Publication number: 20220073919
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 10, 2022
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Therapeutic oligonucleotides
    Patent number: 11091765
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 17, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Therapeutic oligonucleotides
    Patent number: 10941176
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 9, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Günter Mayer, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20210062191
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Application
    Filed: June 10, 2020
    Publication date: March 4, 2021
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Heather O'Neill, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20200376022
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include circulating biomarkers such as micro vesicles, including those derived from various diseases.
    Type: Application
    Filed: March 27, 2018
    Publication date: December 3, 2020
    Applicant: Caris Science, Inc.
    Inventors: Valeriy Domenyuk, Xianghua Liu, Mark Miglarese, David Spetzler
  • Methods for typing of lung cancer
    Patent number: 10829819
    Abstract: Methods and compositions are provided for the molecular subtyping of lung cancer samples. Specifically, a method of assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, or a neuroendocrine (encompassing both small cell carcinoma and carcinoid) is provided herein. A method for assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, small cell carcinoma or carcinoid lung cancer is also provided. The methods provided herein entail probing the levels of the classifier biomarkers of Table 1-Table 6 or a subset thereof at the nucleic acid level, in a lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample is classified as a particular lung cancer subtype.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 10, 2020
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Myla Lai-Goldman, Gregory Mayhew, Charles Perou, David Neil Hayes, Cheng Fan, Mark Miglarese
  • Therapeutic Oligonucleotides
    Publication number: 20200277606
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Application
    Filed: February 6, 2020
    Publication date: September 3, 2020
    Inventors: Heather O`Neill, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20200270610
    Abstract: Methods and compositions are provided for oligonucleotide probes and oligonucleotide probe libraries that recognize targets of interest. The targets include circulating biomarkers such as microvesicles, including those derived from various diseases.
    Type: Application
    Filed: November 25, 2019
    Publication date: August 27, 2020
    Applicant: Caris Science, Inc.
    Inventors: Valeriy DOMENYUK, Adam STARK, Nianqing XIAO, Zhenyu ZHONG, Mark MIGLARESE, David SPETZLER
  • Oligonucleotide probes and uses thereof
    Patent number: 10731166
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 18, 2017
    Date of Patent: August 4, 2020
    Assignee: Caris Science, Inc.
    Inventors: Valeriy Domenyuk, Tassilo Hornung, Heather O'Neill, Mark Miglarese, David Spetzler
  • Therapeutic oligonucleotides
    Patent number: 10590425
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 17, 2020
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Oligonucleotide Probes and Uses Thereof
    Publication number: 20200032265
    Abstract: Methods and compositions are provided for oligonucleotides and libraries of oligonucleotides that bind targets of interest. The targets include cellular biomarkers of viral infection. The viral infection may be that of human immunodeficiency virus-1.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 30, 2020
    Inventors: Tassilo Hornung, Heather O'Neill, Mark Miglarese, David Spetzler
  • OLIGONUCLEOTIDE PROBES AND USES THEREOF
    Publication number: 20190367903
    Abstract: Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.
    Type: Application
    Filed: May 25, 2017
    Publication date: December 5, 2019
    Inventors: Valeriy DOMENYUK, Tassilo HORNUNG, Mark MIGLARESE, David SPETZLER
  • TARGETED OLIGONUCLEOTIDES
    Publication number: 20190359983
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a member of a ribonucleoprotein or spliceosomal complex such heterologous nuclear ribonucleoprotein U (hnRNP U).
    Type: Application
    Filed: February 2, 2018
    Publication date: November 28, 2019
    Inventors: Heather O'Neill, Günter Mayer, Sonal Tonapi, Vaishali Pannu, Mark Miglarese, David Spetzler